Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

179 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.
Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM. Roskell NS, et al. Thromb Haemost. 2010 Dec;104(6):1106-15. doi: 10.1160/TH10-10-0642. Epub 2010 Oct 21. Thromb Haemost. 2010. PMID: 20967400
Patients with atrial fibrillation at moderate to high risk of stroke are not always anticoagulated despite a lack of contraindications to vitamin K antagonists (VKAs) like warfarin. ...A network meta-analysis (NMA) was performed to indirectly compare dabigatran etex …
Patients with atrial fibrillation at moderate to high risk of stroke are not always anticoagulated despite a lack of contraindication …
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA, Dolan G, Brenkel IJ. Wolowacz SE, et al. Thromb Haemost. 2010 Feb;103(2):360-71. doi: 10.1160/TH09-08-0579. Epub 2009 Dec 18. Thromb Haemost. 2010. PMID: 20024501
We investigated the cost-effectiveness of the 150 mg once daily (od) dose recommended for patients aged over 75 or with moderate renal impairment, from a United Kingdom National Health Service perspective. Dabigatran etexilate was compared with subcutaneous enoxaparin 40 m …
We investigated the cost-effectiveness of the 150 mg once daily (od) dose recommended for patients aged over 75 or with moderate renal impai …
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, Clemens A, Hantel S, Schnee JM, Eriksson BI; RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees. Friedman RJ, et al. Thromb Res. 2010 Sep;126(3):175-82. doi: 10.1016/j.thromres.2010.03.021. Epub 2010 May 15. Thromb Res. 2010. PMID: 20434759
OBJECTIVES AND METHODS: We conducted a pre-specified pooled analysis of these trials. 8,210 patients were randomized, of whom 8,135 were treated (evaluable for safety) with dabigatran 220 mg or 150 mg once-daily, or subcutaneous enoxaparin (40 mg once-daily or 30 mg twice- …
OBJECTIVES AND METHODS: We conducted a pre-specified pooled analysis of these trials. 8,210 patients were randomized, of whom 8,135 w …
Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients.
Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Gallagher AM, et al. Thromb Haemost. 2011 Nov;106(5):968-77. doi: 10.1160/TH11-05-0353. Epub 2011 Sep 8. Thromb Haemost. 2011. PMID: 21901239
Patients who spent at least 70% of time within therapeutic range had a 79% reduced risk of stroke compared to patients with ≤30% of time in range (adjusted relative rate of 0.21; 95% confidence interval 0.18-0.25). ...In conclusion, good anticoagulation control was associa …
Patients who spent at least 70% of time within therapeutic range had a 79% reduced risk of stroke compared to patients with ≤30% of t …
Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation.
Sinnaeve PR, Brueckmann M, Clemens A, Oldgren J, Eikelboom J, Healey JS. Sinnaeve PR, et al. J Intern Med. 2012 Jan;271(1):15-24. doi: 10.1111/j.1365-2796.2011.02464.x. Epub 2011 Oct 31. J Intern Med. 2012. PMID: 21995885 Review.
Failure to initiate VKA in elderly AF patients is related to a number of factors, including the limitations of current therapies and the increased risk for major haemorrhage associated with advanced age and anticoagulation therapy. ...Amongst these new agents, the recently …
Failure to initiate VKA in elderly AF patients is related to a number of factors, including the limitations of current therapies and …
Stroke prevention in atrial fibrillation--an Asian stroke perspective.
Tse HF, Wang YJ, Ahmed Ai-Abdullah M, Pizarro-Borromeo AB, Chiang CE, Krittayaphong R, Singh B, Vora A, Wang CX, Zubaid M, Clemens A, Lim P, Hu D. Tse HF, et al. Heart Rhythm. 2013 Jul;10(7):1082-8. doi: 10.1016/j.hrthm.2013.03.017. Epub 2013 Mar 15. Heart Rhythm. 2013. PMID: 23501173 Review.
Despite relatively lower prevalence of atrial fibrillation (AF) in Asians (~1%) than in Caucasians (~2%), Asia has a much higher overall disease burden because of its proportionally larger aged population. ...Stroke is a disabling complication of AF that is of incre …
Despite relatively lower prevalence of atrial fibrillation (AF) in Asians (~1%) than in Caucasians (~2%), Asia has a much higher over …
Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control.
Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Morgan CL, et al. Thromb Res. 2009 May;124(1):37-41. doi: 10.1016/j.thromres.2008.09.016. Epub 2008 Dec 4. Thromb Res. 2009. PMID: 19062079
MATERIAL AND METHODS: The study used a retrospective cohort design using linked inpatient, haematology and mortality data from Cardiff and the Vale of Glamorgan, UK. ...CONCLUSIONS: Patients with INR control of above 70% of time in range had a significantly reduced …
MATERIAL AND METHODS: The study used a retrospective cohort design using linked inpatient, haematology and mortality data from Cardif …
Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes.
Gallagher AM, van Staa TP, Murray-Thomas T, Schoof N, Clemens A, Ackermann D, Bartels DB. Gallagher AM, et al. BMJ Open. 2014 Jan 27;4(1):e003839. doi: 10.1136/bmjopen-2013-003839. BMJ Open. 2014. PMID: 24468720 Free PMC article.
OBJECTIVES: Atrial fibrillation (AF) is the most common cardiac rhythm disorder with a significant health burden. The aim of this study was to characterise patients with recently diagnosed AF and to estimate the rates of comorbidities and outcome events requiring hospitali …
OBJECTIVES: Atrial fibrillation (AF) is the most common cardiac rhythm disorder with a significant health burden. The aim of this stu …
Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference.
Kirchhof P, Breithardt G, Aliot E, Al Khatib S, Apostolakis S, Auricchio A, Bailleul C, Bax J, Benninger G, Blomstrom-Lundqvist C, Boersma L, Boriani G, Brandes A, Brown H, Brueckmann M, Calkins H, Casadei B, Clemens A, Crijns H, Derwand R, Dobrev D, Ezekowitz M, Fetsch T, Gerth A, Gillis A, Gulizia M, Hack G, Haegeli L, Hatem S, Häusler KG, Heidbüchel H, Hernandez-Brichis J, Jais P, Kappenberger L, Kautzner J, Kim S, Kuck KH, Lane D, Leute A, Lewalter T, Meyer R, Mont L, Moses G, Mueller M, Münzel F, Näbauer M, Nielsen JC, Oeff M, Oto A, Pieske B, Pisters R, Potpara T, Rasmussen L, Ravens U, Reiffel J, Richard-Lordereau I, Schäfer H, Schotten U, Stegink W, Stein K, Steinbeck G, Szumowski L, Tavazzi L, Themistoclakis S, Thomitzek K, Van Gelder IC, von Stritzky B, Vincent A, Werring D, Willems S, Lip GY, Camm AJ. Kirchhof P, et al. Europace. 2013 Nov;15(11):1540-56. doi: 10.1093/europace/eut232. Epub 2013 Aug 27. Europace. 2013. PMID: 23981824
During the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association (AFNET/EHRA) consensus conference, we identified the following opportunities to personalize management of AF in a better manner with a view to improve outcomes by integrating …
During the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association (AFNET/EHRA) consensus conference, we identified …
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database.
Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S. Lip GY, et al. Thromb Haemost. 2014 May 5;111(5):933-42. doi: 10.1160/TH13-09-0734. Epub 2013 Dec 11. Thromb Haemost. 2014. PMID: 24326736
Thus, adherence to European label/guideline use results in a clinically relevant benefit for dabigatran over warfarin, for both efficacy and safety....
Thus, adherence to European label/guideline use results in a clinically relevant benefit for dabigatran over warfarin, for both effic …
179 results
Jump to page
Feedback